Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $29.05M |
| Net Income (Most Recent Fiscal Year) | $-171.98M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 708.18 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -4259.30% |
| Net Margin (Trailing 12 Months) | -1839.58% |
| Return on Equity (Trailing 12 Months) | -16.43% |
| Return on Assets (Trailing 12 Months) | -15.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 33.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 33.70 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.45 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.40 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.17 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.56 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 695.49M |
| Free Float | 620.38M |
| Market Capitalization | $14.40B |
| Average Volume (Last 20 Days) | 6.90M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 64.76% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |